{"id":114735,"date":"2019-06-11T12:13:32","date_gmt":"2019-06-11T04:12:42","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/114735\/"},"modified":"2019-06-11T12:12:50","modified_gmt":"2019-06-11T04:12:50","slug":"9a45be0a71","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/114735\/","title":{"rendered":"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6 \u2014 ASCO \u4e2d\u56fd\u4e73\u817a\u764c\u5b66\u8005\u7684\u58f0\u97f3"},"content":{"rendered":"
\n
\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n

\n
\n
\n
\n
\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/section>\n<\/section>\n<\/section>\n
\n


<\/p>\n

\u4e00\u5e74\u56db\u5b63\u7684\u66f4\u8fed\u4f34\u968f\u7684\u662f\u65b0\u4e00\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u5e74\u4f1a\uff08American Society of Clinicail Oncology, ASCO\uff09\u7684\u53ec\u5f00\u3002\u6e90\u81ea\u5927\u6d0b\u5f7c\u5cb8\u5439\u6765\u7684\u4e0d\u4ec5\u662f\u548c\u7166\u7684\u6696\u98ce\uff0c\u662f\u5bf9\u751f\u6d3b\u7684\u5411\u5f80\uff0c\u662f\u5bf9\u672a\u6765\u7684\u5e0c\u671b\uff0c\u66f4\u662f\u5bf9\u751f\u547d\u7684\u793c\u8d5e\u3002<\/span><\/p>\n


<\/p>\n

\u8fc7\u53bb\u4e00\u5e74\uff0c\u968f\u7740\u5e15\u6258\u73e0\u5355\u6297\uff08Pertuzumab\uff09\u5728\u4e2d\u56fd\u4e0a\u5e02\u3001CDK4\/6 \u6291\u5236\u5242\u54cc\u67cf\u897f\u5229\uff08Palbociclib\uff09\u7684\u767b\u9646\u3001\u81ea\u8a00\u7814\u53d1\u65b0\u836f\u5421\u54af\u66ff\u5c3c\uff08Pyrotinib\uff09\u7684\u6210\u529f\u7b49\u4e00\u7cfb\u5217\u632f\u594b\u4eba\u5fc3\u7684\u6d88\u606f\uff0c\u7740\u5b9e\u8ba9\u5e7f\u5927\u4e0d\u5e78\u7f79\u60a3\u4e73\u817a\u764c\u60a3\u8005\u300c\u4e73\u300d\u6b64\u7f8e\u597d\u7684\u751f\u6d3b\u66f4\u8fdb\u4e00\u6b65\uff0c\u751f\u6d3b\u8d28\u91cf\u66f4\u4e0a\u4e00\u5c42\u697c\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u4e0b\u9762\u6211\u4eec\u5bf9\u4eca\u5e74\u5728 ACSO \u5927\u4f1a\u4e0a\u51e0\u4f4d\u4e2d\u56fd\u5b66\u8005\u5173\u4e8e\u300c\u7c89\u7ea2\u6740\u624b\u300d\u4e73\u817a\u764c\u7684\u4e3b\u8981\u7814\u7a76\u53d1\u8a00\u8fdb\u884c\u603b\u7ed3\u548c\u68b3\u7406\uff0c\u4e86\u89e3\u6700\u65b0\u7684\u7814\u7a76\u8fdb\u5c55\u3002<\/p>\n


<\/p>\n

 \u5421\u54af\u66ff\u5c3c\u5439\u8d77 HER2+ MBC \u7684\u51b2\u950b\u53f7 <\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u4f17\u6240\u5468\u77e5\uff0c\u4e73\u817a\u764c\u4e2d HER2 \u9633\u6027\u4e73\u817a\u764c\u662f\u4e00\u79cd\u51f6\u9669\u7a0b\u5ea6\u5f88\u9ad8\u7684\u4e73\u817a\u764c\uff0c\u8fd9\u7c7b\u80bf\u7624\u7edd\u5927\u90e8\u5206\u4f9d\u8d56\u4e8e HER2 \u901a\u8def\u6765\u9a71\u52a8\u80bf\u7624\u7ec6\u80de\u7684\u589e\u6b96\uff0c\u7ea6 20%\uff5e30% \u7684\u4e73\u817a\u764c\u60a3\u8005\u5b58\u5728 HER2 \u57fa\u56e0\u7684\u6269\u589e\u53ca\u5176\u7f16\u7801\u86cb\u767d\u7684\u8fc7\u8868\u8fbe\uff0c\u4e0e\u80bf\u7624\u4fb5\u88ad\u6027\u5f3a\u3001\u590d\u53d1\u7387\u9ad8\u3001\u9884\u540e\u4e0d\u826f\u6709\u5173\u3002<\/p>\n


<\/p>\n

\u5421\u54af\u66ff\u5c3c\uff08Pyrotinib\uff09\u662f\u7531\u6211\u56fd\u81ea\u4e3b\u7814\u53d1\u7684\u65b0\u4e00\u4ee3\u6297 HER2 \u6cbb\u7597\u9776\u5411\u836f\uff0c\u5176\u65e2\u5f80\u5b8c\u6210\u7684\u4e34\u5e8a\u2160\u671f\u7814\u7a76\u4e8e 2017 \u5e74 5 \u6708\u5728\u300aJournal of Clinical Oncology\uff08\u4e34\u5e8a\u80bf\u7624\u5b66\u6742\u5fd7\uff09\u300b\u53d1\u8868\uff0c\u540c\u5e74\u7f8e\u56fd\u5723\u5b89\u4e1c\u5c3c\u5965\u4e73\u817a\u764c\u5927\u4f1a (San Antonio Breast Cancer Symposium, SABCS) \u4e0a\u516c\u5e03\u4e86\u5176\u2161\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u8bc1\u660e\u4e86\u5728 HER2+ \u8f6c\u79fb\u6027\u4e73\u817a\u764c\uff08Metastatic breast cance\uff0cMBC\uff09\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u548c\u53ef\u63a5\u53d7\u7684\u8010\u53d7\u6027\u3002<\/p>\n


<\/p>\n

\u6b64\u6b21\u5927\u4f1a\uff0c\u7531\u4e2d\u56fd\u4eba\u6c11\u89e3\u653e\u519b\u603b\u533b\u9662\u7b2c\u4e94\u533b\u5b66\u4e2d\u5fc3\u6c5f\u6cfd\u98de\u6559\u6388\u6c47\u62a5\u7684\u300a\u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u6cbb\u7597\u65e2\u5f80\u63a5\u53d7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u7d2b\u6749\u7c7b\u836f\u7269\u6cbb\u7597\u7684 HER2 \u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\uff1a\u4e00\u9879\u968f\u673a\u7684\u0428\u671f\u4e34\u5e8a\u7814\u7a76\u300b\uff08Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study\uff09(\u4e34\u5e8a\u8bd5\u9a8c\u4fe1\u606f NCT 02973737) \u516c\u5e03\u4e86\u5176\u7814\u7a76\u7ed3\u679c\u3002<\/p>\n


<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n


<\/p>\n

 \u7814\u7a76\u65b9\u6cd5 <\/span><\/p>\n


<\/p>\n

\u8fd9\u9879\u53cc\u76f2\u3001\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u7684 III \u671f\u8bd5\u9a8c\uff0c\u662f\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u7d2b\u6749\u7c7b\u836f\u7269\u548c\u6297 HER2 \u7ecf\u5178\u9776\u5411\u836f\u7269\u66f2\u59a5\u73e0\u5355\u6297\u6cbb\u7597\u540e\u7684 HER2 +\u8f6c\u79fb\u6027\u4e73\u817a\u764c\uff08MBC\uff09\u60a3\u8005\u4e2d\u8fdb\u884c\u7684\u3002\u5728 2016 \u5e74 7 \u6708\u81f3 2017 \u5e74 11 \u6708\u671f\u95f4\uff0c279 \u540d\u60a3\u8005\u4ee5 2\uff1a1 \u968f\u673a\u5206\u914d\u81f3\u6bcf\u5929\u4e00\u6b21\u53e3\u670d 400 mg \u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\uff08n = 185\uff09\u6216\u5b89\u6170\u5242\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\uff08n = 94\uff09\u7ec4\uff0c\u5361\u57f9\u4ed6\u6ee8\u7528\u6cd5\u4e3a 1000 mg \/ m2\uff0c\u6bcf\u5929\u53e3\u670d\u4e24\u6b21\uff0c\u7b2c 1-14 \u5929\uff0c\u4ee5\u4e0a\u6cbb\u7597\u4ee5 21 \u5929\u4e3a\u4e00\u4e2a\u5468\u671f\u3002<\/p>\n


<\/p>\n

\u5728\u63a5\u53d7\u81f3\u5c11 1 \u4e2a\u6cbb\u7597\u5468\u671f\u7684\u60a3\u8005\u4e2d\u8bc4\u4f30\u4e3b\u8981\u7ec8\u70b9\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08progression-free survival, PFS\uff09\u3002\u6b64\u5916\uff0c\u5728\u670d\u7528\u5b89\u6170\u5242\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u7684\u60a3\u8005\u5728\u75c5\u60c5\u8fdb\u5c55\u540e\u63a5\u53d7\u5355\u836f\u5421\u54af\u66ff\u5c3c\u6cbb\u7597\u3002<\/p>\n


<\/p>\n

 \u7814\u7a76\u7ed3\u679c <\/span><\/p>\n


<\/p>\n

\u7ed3\u679c\u8868\u660e\uff0c\u5728\u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u7ec4\u7684\u4e2d\u4f4d PFS \u4e3a 11.1 \u4e2a\u6708\uff0895%CI 9.66,16.53\uff09\uff0c\u5b89\u6170\u5242\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u7ec4\u4e3a 4.1 \u4e2a\u6708\uff0895%CI 2.79,4.17\uff09\u3002<\/p>\n


<\/p>\n

71 \u4f8b\u5b89\u6170\u5242\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u7ec4\u60a3\u8005\u63a5\u53d7\u968f\u540e\u7684\u5421\u7f57\u66ff\u5c3c\u6cbb\u7597\uff0c\u5355\u836f\u53cd\u5e94\u7387\u4e3a 38.0%\uff0895%CI 26.7%\uff0c49.3%\uff09\uff0c\u4e2d\u4f4d PFS \u4e3a 5.5 \u4e2a\u6708\uff0895%CI 4.07,6.90\uff09\u3002<\/p>\n


<\/p>\n

\u6700\u5e38\u89c1\uff08\u2265 5%\uff09\u4e0e\u6cbb\u7597\u76f8\u5173 \u2265 3 \u7ea7\u4e0d\u826f\u4e8b\u4ef6\u4e3a\uff1a\u8179\u6cfb\uff0830.8%vs 12.8%\uff09\u548c\u624b\u8db3\u7efc\u5408\u5f81\uff0815.7%vs 5.3%\uff09\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u5982\u4e0b\u56fe\u6240\u793a\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n

<\/span>\u25b3\u56fe 1<\/span><\/p>\n


<\/p>\n

 \u603b\u7ed3 <\/span><\/p>\n


<\/p>\n

\u4ee5\u4e0a\u7ed3\u8bba\u5145\u5206\u8868\u660e\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u7d2b\u6749\u7c7b\u836f\u7269\u548c\u66f2\u59a5\u73e0\u5355\u6297\u6cbb\u7597\u7684 HER2 + MBC \u5973\u6027\u4e2d\uff0c\u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u5728\u7edf\u8ba1\u5b66\u4e0a\u663e\u7740\u66f4\u597d\u7684 PFS\uff0c\u5421\u54af\u66ff\u5c3c\u5355\u836f\u6cbb\u7597\u663e\u793a\u51fa\u8f83\u597d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002<\/p>\n


<\/p>\n

\n


<\/p>\n

 \u5e15\u59a5\u73e0\u5355\u6297\u767b\u4e0a\u4e2d\u56fd\u6297 HER2 \u4e00\u7ebf\u6cbb\u7597\u7684\u821e\u53f0 <\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u7531\u56fd\u5bb6\u764c\u75c7\u4e2d\u5fc3\/\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u80bf\u7624\u533b\u9662\u5f90\u5175\u6cb3\u6559\u6388\u9886\u8854\u7684\u300a\u5bf9\u672a\u7ecf\u6cbb\u7597\u7684 HER2 \u9633\u6027\u5c40\u90e8\u590d\u53d1\/\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u4e2d\u5e15\u59a5\u73e0\u5355\u6297\uff08P\uff09+\u66f2\u59a5\u73e0\u5355\u6297\uff08H\uff09+\u591a\u897f\u7d2b\u6749\u9187\uff08D\uff09\u4e0e\u5b89\u6170\u5242\uff08Pla\uff09+ H + D \u7684\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u7684\u4e34\u5e8a\u0428\u671f\u7814\u7a76\uff08PUFFIN\uff09\u300b\uff08A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent\/metastatic breast cancer (LR\/MBC) (PUFFIN)\uff08\u4e34\u5e8a\u8bd5\u9a8c\u4fe1\u606f NCT02896855\uff09\u4e5f\u5728\u6b64\u6b21\u5927\u4f1a\u516c\u5e03\u4e86\u7814\u7a76\u7ed3\u679c\u3002<\/p>\n


<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n


<\/span><\/p>\n

 \u7814\u7a76\u80cc\u666f <\/span><\/p>\n


<\/p>\n

\u5728\u65e2\u5f80\u7684 CLEOPATRA\uff08NCT00567190\uff09\u4e2d\uff0c\u5bf9\u4e8e\u5c40\u90e8\u590d\u53d1\u3001\u65e0\u6cd5\u5207\u9664\u6216\u8f6c\u79fb\u6027 HER-2 \u9633\u6027\u4e73\u817a\u764c\uff0c\u4e00\u7ebf\u66f2\u59a5\u73e0\u5355\u6297\u8054\u5408\u591a\u897f\u4ed6\u8d5b\u65b9\u6848\u7684\u57fa\u7840\u4e0a\u589e\u52a0\u4e86\u5e15\u59a5\u73e0\u5355\u6297\uff0c\u53cc\u9776\u7684\u53cc\u7ba1\u9f50\u4e0b\u4e0e\u5316\u7597\u836f\u7269\u4e09\u8005\u7684\u5f3a\u5f3a\u8054\u5408\u589e\u52a0\u4e86\u5e15\u59a5\u73e0\u5355\u6297\u4f7f\u60a3\u8005\u7684\u4e2d\u4f4d PFS\uff0c\u7ed3\u679c\u8868\u660e\u4ece\u5bf9\u7167\u7ec4\u7684 12.4 \u4e2a\u6708\u589e\u52a0\u81f3 18.5 \u4e2a\u6708\uff0c\u4e2d\u4f4d\u603b\u751f\u5b58\u671f (Overall survival\uff0cOS) \u4ece 40.8 \u4e2a\u6708\u589e\u52a0\u81f3 56.5 \u4e2a\u6708 HR = 0.68\uff0895% CI\uff1a0.56-0.84 p<0.001\uff09\u3002<\/p>\n


<\/span><\/p>\n

 \u7814\u7a76\u65b9\u6cd5 <\/span><\/p>\n


<\/p>\n

\u6b64\u9879\u7684\u4e34\u5e8a\u7814\u7a76\u662f\u4e00\u9879\u4e2d\u56fd\u6865\u63a5\u7814\u7a76\uff0c\u76ee\u7684\u662f\u8bc4\u4f30\u7597\u6548\u4e0e CLEOPATRA \u7684\u4e00\u81f4\u6027\u3002 <\/p>\n


<\/p>\n

\u5bf9\u4e8e\u672a\u7ecf\u6cbb\u7597\u5c40\u90e8\u590d\u53d1\u3001\u65e0\u6cd5\u5207\u9664\u6216\u8f6c\u79fb\u6027 HER-2 \u9633\u6027\u4e73\u817a\u764c\u7684\u60a3\u8005\uff0c\u4ee5 1\uff1a1 \u968f\u673a\u5316\u81f3 P + H + D \u6216 Pla + H + D\uff0c\u4e3b\u8981\u7ec8\u70b9\u662f\u7684 PFS\uff0c\u6b21\u8981\u7ec8\u70b9\u5305\u62ec\u5ba2\u89c2\u7f13\u89e3\u7387 (Objective response rate\uff0cORR)\uff0cOS \u548c\u5b89\u5168\u6027\u3002<\/p>\n


<\/p>\n

\u76ee\u6807\u6837\u672c 240 \u4f8b\u662f\u6839\u636e PFS \u7684\u4e00\u81f4\u6027\u9608\u503c\u786e\u5b9a\u7684\uff0c\u98ce\u9669\u6bd4\uff08HR\uff09<0.81\uff0c\u4fdd\u6301\u5728 CLEOPATRA \u4e2d\u786e\u5b9a\u7684\u98ce\u9669\u964d\u4f4e \u2265 50%\uff08HR 0.62\uff09\u3002<\/p>\n


<\/p>\n

 \u7814\u7a76\u7ed3\u679c <\/span><\/p>\n


<\/p>\n

\u57fa\u7ebf\/\u75be\u75c5\u7279\u5f81\u548c\u5148\u524d\u7684\u6cbb\u7597\u5728\u4e24\u7ec4\u4e4b\u95f4\u57fa\u672c\u4e00\u81f4\u3002<\/p>\n


<\/p>\n

\u5bf9\u4e8e PFS\uff0c\u610f\u5411\u6cbb\u7597\u4eba\u7fa4\uff08Intent to treat, ITT\uff09\u7684 HR \u4e3a 0.69\uff0895%CI 0.49,0.99\uff09\u3002\u6548\u679c\u53ca\u5b89\u5168\u6027\u663e\u793a\u5982\u56fe 2 \u6240\u793a\u3002<\/p>\n


<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n

\u25b3\u56fe 2<\/span><\/p>\n


<\/p>\n

\u7814\u7a76\u6ca1\u6709\u62a5\u544a\u5fc3\u529b\u8870\u7aed\u6216\u75c7\u72b6\u6027\u5de6\u5fc3\u5ba4\u5c04\u8840\u5206\u6570\u4e0b\u964d\u7684\u75c5\u4f8b\u3002\u603b\u4f53\u800c\u8a00\uff0cPUFFIN \u7814\u7a76\u7b26\u5408\u5176\u4e3b\u8981\u7ec8\u70b9\uff0c\u7597\u6548\u6570\u636e\u4e0e CLEOPATRA\uff08ITT \u4eba\u7fa4\u548c\u4e9a\u6d32\u4e9a\u7ec4\uff09\u4e00\u81f4\u3002\u5b89\u5168\u6027\u4e5f\u57fa\u672c\u4e00\u81f4\uff0c\u5e76\u4e14\u4e0e\u5df2\u77e5\u7684\u5b89\u5168\u6027\u66f2\u7ebf\u4e00\u81f4\uff0c\u6ca1\u6709\u62a5\u544a\u65b0\u7684\u6216\u610f\u5916\u7684\u4e8b\u4ef6\u3002<\/p>\n


<\/p>\n

 \u603b\u7ed3 <\/span><\/p>\n


<\/p>\n

PUFFIN \u7814\u7a76\u5bf9\u4e8e\u672a\u7ecf\u6cbb\u7597\u5c40\u90e8\u590d\u53d1\u3001\u65e0\u6cd5\u5207\u9664\u6216\u8f6c\u79fb\u6027 HER-2 \u9633\u6027\u4e73\u817a\u764c\u7684\u60a3\u8005\u800c\u8a00\uff0c\u6269\u5145\u4e86\u5e15\u6258\u73e0\u5355\u6297\u7684\u6570\u636e\u603b\u91cf\uff0c\u5e76\u7528\u6570\u636e\u652f\u6301\u4e86\u4e2d\u56fd\u60a3\u8005\u7684\u5728\u4f7f\u7528\u5e15\u59a5\u73e0\u5355\u6297\u7684\u4e34\u5e8a\u83b7\u76ca\u3002<\/p>\n


<\/p>\n

\n


<\/p>\n

 \u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u518d\u6b21\u767b\u4e0a\u56fd\u9645\u821e\u53f0 <\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u56fd\u5bb6\u764c\u75c7\u4e2d\u5fc3\/\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u80bf\u7624\u533b\u9662\u9a6c\u98de\u6559\u6388\u9886\u8854\u300a\u5728 HER2 \u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u4e2d\u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u7684\u5b89\u5168\u6027\uff0c\u6709\u6548\u6027\u548c\u751f\u7269\u6807\u5fd7\u7269\u5206\u6790\uff1aI \u671f\u4e34\u5e8a\u8bd5\u9a8c\u300b\uff08Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial\uff09\uff08  \u4e34\u5e8a\u8bd5\u9a8c\u4fe1\u606f NCT02361112\uff09\u4e5f\u5728\u6b64\u6b21\u5927\u4f1a\u4e88\u4ee5\u516c\u5e03\u3002<\/p>\n


<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n


<\/p>\n

 \u7814\u7a76\u80cc\u666f <\/span><\/p>\n


<\/p>\n

\u65e2\u5f80 HER2 \u5bb6\u65cf\u4e2d\u7684\u4ea4\u53c9\u4fe1\u53f7\u4f20\u5bfc\u662f\u66f2\u59a5\u73e0\u5355\u6297\u6297\u6027\u7684\u91cd\u8981\u673a\u5236\uff0c\u800c Pyrotinib \u662f\u4e00\u79cd\u4e0d\u53ef\u9006\u8f6c\u7684\u3001\u9488\u5bf9 EGFR \/ HER1\uff0cHER2 \u548c HER4 \u53d7\u4f53\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u53ef\u80fd\u4f1a\u63d0\u9ad8\u963b\u65ad\u66f2\u59a5\u73e0\u5355\u6297\u8010\u836f\u4e73\u817a\u764c\u4e2d HER2 \u4fe1\u53f7\u4f20\u5bfc\u7684\u529f\u6548\u3002<\/p>\n


<\/p>\n

 \u7814\u7a76\u65b9\u6cd5 <\/span><\/p>\n


<\/p>\n

\u8be5 I \u671f\u7814\u7a76\u8bc4\u4f30\u4e86 HER2 \u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\uff08MBC\uff09\u60a3\u8005\u4e2d\u5421\u54af\u66ff\u5c3c\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u3001\u6700\u5927\u8010\u53d7\u5242\u91cf\uff08MTD\uff09\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u3001\u6297\u80bf\u7624\u6d3b\u6027\u548c\u9884\u6d4b\u751f\u7269\u6807\u5fd7\u7269\u3002<\/p>\n


<\/p>\n

\u60a3\u8005\u5728\u4ee5 21 \u5929\u4e3a 1 \u5468\u671f\u7684\u6cbb\u7597\u4e2d\uff0c\u7b2c 1 \u81f3 14 \u5929\u53e3\u670d\u5421\u54af\u66ff\u5c3c 160 mg\u3001240 mg\u3001320 mg \u6216 400 mg\uff0c\u6bcf\u5929\u4e24\u6b21\u8054\u5408\u5361\u57f9\u4ed6\u6ee8\uff081000 mg \/ m2\uff09\u6cbb\u7597\u3002\u5728\u6cbb\u7597\u7684\u7b2c 1 \u5929\u548c\u7b2c 14 \u5929\u62bd\u8840\u83b7\u53d6\u836f\u4ee3\u52a8\u529b\u5b66\u4fe1\u606f\u3002\u5bf9\u5faa\u73af\u80bf\u7624 DNA\uff08ctDNA\uff09\u8fdb\u884c\u65b0\u4e00\u4ee3\u6d4b\u5e8f\uff08NGS\uff09\u68c0\u6d4b\u4ee5\u63a2\u5bfb\u8be5\u7ec4\u5408\u53ef\u80fd\u5b58\u5728\u7684\u9884\u6d4b\u6027\u751f\u7269\u6807\u5fd7\u7269\u3002<\/p>\n


<\/p>\n

\u6b64\u7814\u7a76\u5171\u62db\u52df\u4e86 28 \u540d\u53d7\u8bd5\u8005\uff0c\u6240\u6709\u60a3\u8005\u90fd\u7ecf\u5386\u8fc7\u81f3\u5c11\u4e00\u6b21\u4e0e\u6cbb\u7597\u76f8\u5173\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08AE\uff09\uff0c\u5176\u4e3b\u8981\u4e3a 1 \u7ea7\u6216 2 \u7ea7\u30023 \u7ea7\u6cbb\u7597\u76f8\u5173\u7684 AE \u53d1\u751f\u4e8e 12 \u540d\uff0842.9%\uff09\u60a3\u8005\u4e2d\uff0c\u5176\u4e2d\u8d2b\u8840\uff0814.3%\uff09\u548c\u8179\u6cfb\uff0810.7%\uff09\u662f\u6700\u5e38\u89c1\u7684 3 \u7ea7 AE\u30023 \u540d\uff0810.7%\uff09\u60a3\u8005\u56e0 AE \u800c\u505c\u7528\u5361\u57f9\u4ed6\u6ee8\u3002 <\/p>\n


<\/p>\n

 \u7814\u7a76\u7ed3\u679c <\/span><\/p>\n


<\/p>\n

\u603b ORR \u4e3a 78.6%\uff0895%CI\uff1a59.0%-91.7%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387 (Disease control rate, DCR) \u4e3a 96.4%\uff0895%CI\uff1a81.7%-99.9%\uff09\u3002\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u4e3a 22.1 \u4e2a\u6708\uff0895%CI\uff1a9.0-26.2 \u4e2a\u6708\uff09\u3002\u65e2\u5f80\u63a5\u53d7\u8fc7\u66f2\u59a5\u73e0\u5355\u6297\u6cbb\u7597\u7684\u60a3\u8005 ORR \u4e3a 70.6%\uff0812\/17\uff09\uff0c\u672a\u63a5\u53d7\u8fc7\u66f2\u59a5\u73e0\u5355\u6297\u6cbb\u7597\u60a3\u8005\u7684 ORR \u4e3a 90.9%\uff0810\/11\uff09\u3002<\/p>\n


<\/p>\n

\u5bf9\u57fa\u7ebf\u8840\u6db2\u6837\u672c\u4e2d HER2 \u65c1\u8def\u4fe1\u53f7\u901a\u8def\uff0cPI3K \/ Akt \/ mTOR \u901a\u8def\u548c TP53 \u7684\u6240\u6709\u9057\u4f20\u6539\u53d8\u7684 NGS \u5206\u6790\u8868\u660e\uff0c\u4e0e\u6ca1\u6709\u6216 1 \u4e2a\u9057\u4f20\u6539\u53d8\u76f8\u6bd4\uff0c\u4f34\u968f\u7684\uff08\u4e24\u4e2a\u6216\u66f4\u591a\uff09\u9057\u4f20\u6539\u53d8\u4e0e\u8f83\u5dee\u7684 PFS \u663e\u7740\u76f8\u5173\uff08\u4e2d\u4f4d 15.8 \u5bf9 26.2 \u4e2a\u6708\uff0cp = 0.006\uff09\u3002<\/p>\n


<\/p>\n

 \u603b\u7ed3 <\/span><\/p>\n


<\/p>\n

\u8bd5\u9a8c\u8868\u660e\u5421\u54af\u66ff\u5c3c\u4e0e\u5361\u57f9\u4ed6\u6ee8\u7684\u7ec4\u5408\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5e76\u4e14\u5728 HER2 \u9633\u6027 MBC \u60a3\u8005\u4e2d\u663e\u793a\u51fa\u4e00\u5b9a\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002 <\/p>\n


<\/p>\n

\n


<\/p>\n

\n
\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/section>\n<\/section>\n


<\/p>\n

Karnofsky \u7eaa\u5ff5\u5956\u662f ASCO \u5e74\u4f1a\u4e0a\u6700\u91cd\u8981\u3001\u6700\u5177\u5206\u91cf\u7684\u5956\u9879\uff0c\u8bbe\u7acb\u521d\u8877\u662f\u7eaa\u5ff5\u7f8e\u56fd\u533b\u5b66\u53f2\u4e0a\u73b0\u4ee3\u80bf\u7624\u5b66\u7684\u5f00\u62d3\u8005\u548c\u5960\u57fa\u8005\u4e4b\u4e00 DAVID A.Karnofsky\u30021970 \u5e74\uff0cASCO \u6c38\u4e45\u8bbe\u7acb Karnofsky \u7eaa\u5ff5\u5956\uff0c\u4ee5\u8868\u5f70\u90a3\u4e9b\u5728\u764c\u75c7\u7814\u7a76\u3001\u8bca\u65ad\u548c\u6cbb\u7597\u9886\u57df\u505a\u51fa\u6770\u51fa\u8d21\u732e\u7684\u80bf\u7624\u5b66\u5bb6\u3002<\/p>\n


<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n

\u25b3 Gabriel N. Hortobagyi \u535a\u58eb<\/span><\/p>\n


<\/p>\n

\u4eca\u5e74\u6765\u81ea MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u7684 Gabriel N. Hortobagyi \u535a\u58eb\u83b7\u5f97\u6b64\u5956\uff0c\u4ed6\u5728\u53d1\u8a00\u4e2d\u8bf4\u9053\uff1a\u6b63\u662f\u7531\u4e8e\u79d1\u5b66\u7684\u8fdb\u6b65\uff0c\u4e73\u817a\u764c\u7684\u6cbb\u7597\u548c\u7ba1\u7406\u524d\u666f\u53d1\u751f\u4e86\u5de8\u5927\u53d8\u5316\u3002\u4e34\u5e8a\u548c\u5206\u5b50\u4e9a\u578b\u6307\u5bfc\u6211\u4eec\u5bf9\u539f\u53d1\u4e73\u817a\u764c\u8fdb\u884c\u5168\u8eab\u6cbb\u7597\u7684\u65b9\u6cd5\uff0c\u4f7f\u5f97\u6211\u4eec\u5c06\u7f13\u89e3\u3001\u6539\u5584\u8f6c\u5316\u4e3a\u63d0\u9ad8\u7684\u6cbb\u6108\u7387\u3002\u5c55\u671b\u672a\u6765\uff0c\u6cbb\u7597\u836f\u7269\u540d\u5355\u8d8a\u6765\u8d8a\u591a\uff0c\u8fd9\u8868\u660e\u6211\u4eec\u786e\u4fe1\u6b63\u8d70\u5728\u6b63\u786e\u7684\u8f68\u9053\u4e0a\u3002<\/p>\n


<\/p>\n

\n
\n
\n
\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n
\n
\n
\n
\n
\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/section>\n
\u6809\u98ce\u6c90\u96e8\u3001\u7825\u783a\u524d\u884c\uff0c\u4e94\u5341\u5e74\u867d\u7136\u4ec5\u4ec5\u662f\u4eba\u7c7b\u65f6\u95f4\u957f\u6cb3\u4e2d\u5fae\u4e0d\u8db3\u9053\u7684\u4e00\u6bb5\uff0c\u4f46\u5374\u662f\u80bf\u7624\uff0c\u7279\u522b\u662f\u4e73\u817a\u764c\u9886\u57df\u8fdb\u5c55\u6700\u5feb\u7684\u534a\u4e2a\u4e16\u7eaa\u3002\u540c\u65f6\u6211\u4eec\u575a\u4fe1\uff0c\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6\uff0cASCO \u4e2d\u56fd\u4e73\u817a\u764c\u5b66\u8005\u7684\u58f0\u97f3\u4e5f\u4f1a\u8d8a\u6765\u8d8a\u54cd\u4eae\u3002<\/span><\/section>\n<\/section>\n
\n
\n
<\/section>\n
\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
\n
\n
\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n

\u672c\u6587\u4f5c\u8005\uff1a\u674e\u6d9b<\/p>\n

\u4e2d\u56fd\u4eba\u6c11\u89e3\u653e\u519b\u603b\u533b\u9662\u7b2c\u4e00\u533b\u5b66\u4e2d\u5fc3\u80bf\u7624\u5185\u79d1<\/p>\n

drtaolee@outlook.com<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u7f16\u8f91\uff1adecie | \u8d23\u4efb\u7f16\u8f91\uff1a\u738b\u5f18<\/span><\/p>\n

\u6295\u7a3f\uff1adecie@qq.com<\/span>
<\/p>\n

\u9898\u56fe\uff1a\u7ad9\u9177\u6d77\u6d1bplus<\/span><\/span><\/p>\n


<\/p>\n


<\/p>\n

\u63a8\u8350\u9605\u8bfb\uff1a<\/strong><\/span><\/p>\n

ASCO | \u4e2d\u56fd\u5b66\u8005\u62a5\u9053\u9f3b\u54bd\u764c\u6cbb\u7597\u65b0\u65b9\u6848<\/a><\/span><\/p>\n

ASCO | DDR \u901a\u8def\u7684\u300c\u673a\u9047\u4e0e\u6311\u6218\u300d<\/a><\/p>\n

ASCO | \u80c3\u80a0\u9053\u80bf\u7624\u4e24\u5927\u65b0\u770b\u70b9<\/span><\/a><\/p>\n


<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n

\"\u4f17\u91cc\u5bfb\u5979\u5343\u767e\u5ea6<\/p>\n

\u53c2\u8003\uff1a<\/span><\/p>\n

https:\/\/abstracts.asco.org\/239\/AbstView_239_253129.html<\/span><\/p>\n

https:\/\/abstracts.asco.org\/239\/AbstView_239_267835.html<\/span><\/p>\n<\/section>\n

https:\/\/dailynews.ascopubs.org\/do\/10.1200\/ADN.19.190305\/full<\/span><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u4e00\u5e74\u56db\u5b63\u7684\u66f4\u8fed\u4f34\u968f\u7684\u662f\u65b0\u4e00\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u5e74\u4f1a\uff08American Society of Clinicail O […]<\/p>\n","protected":false},"author":1,"featured_media":114736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/114735"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=114735"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/114735\/revisions"}],"predecessor-version":[{"id":114752,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/114735\/revisions\/114752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/114736"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=114735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=114735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=114735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}